{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:27:38Z","timestamp":1787203658340,"version":"build-2736575974"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s623621","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:20:12Z","timestamp":1787203212000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China\u2019s Drug Evaluation and Selection Guideline"],"prefix":"10.2147","volume":"Volume 20","author":[{"given":"Zhijun","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0343-3795","authenticated-orcid":true,"given":"Zhuojia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8]]},"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/118489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/118489","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:20:12Z","timestamp":1787203212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/clinical-evaluation-of-anaplastic-lymphoma-kinase-alk-inhibitors-for-t-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dddt.s623621","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}